Background. Current Streptococcus pneumoniae vaccines selectively target capsular polysaccharide of specific serotypes, leading to an increase in nonencapsulated S. pneumoniae (NESp). Cocolonization by encapsulated pneumococci and NESp increases the opportunity for intraspecies genetic exchange. Acquisition of NESp genes by encapsulated pneumococci could alter virulence and help vaccine-targeted serotypes persist in the host.
Streptococcus pneumoniae (the pneumococcus) is a Grampositive bacterium that commonly colonizes the nasopharynx of humans [1] . Pneumococcal isolates can be divided into encapsulated and nonencapsulated strains based on the presence or absence of a polysaccharide capsule. Encapsulated strains are separated into serotypes based on the arrangement and composition of the polysaccharide capsule, and thus far more than 97 antigenically distinct serotypes have been identified [2, 3] .
Strains that do not demonstrate serological evidence of capsule expression are considered nontypeable (NT) and are classified into 2 nonencapsulated S. pneumoniae (NESp) groups [4] . Group I NESp have the characteristic capsule polysaccharide synthesis (cps) locus found in encapsulated pneumococci, but disruptions or mutations prevent functional capsule production [3, 5] . In contrast, group II NESp lack cps genes altogether and instead carry unique genes that encode distinct pneumococcal virulence proteins [3, 5, 6] .
Although pneumococci often colonize the nasopharynx asymptomatically, dissemination from the nasopharynx can lead to disease development and cause serious complications in the very young, elderly, and immunocompromised [7, 8] . Pneumococcal-associated illnesses include pneumonia, otitis media (OM), sinusitis, bacteremia, and meningitis [7, 9] . Currently, 2 pneumococcal vaccines are licensed for use in the United States: Prevnar13 and Pneumovax23 [10] . These vaccines target the capsular polysaccharide of 13 or 23 invasive disease-associated serotypes, respectively [11] . However, even with vaccine implementation, certain disease rates, such as those for OM and noninvasive pneumonia, remain high [12] [13] [14] . The continual occurrence of pneumococcal infections regardless of vaccine administration is due to increased colonization by nonvaccine serotypes and NESp, as well as genetic alterations in vaccine serotypes [15] [16] [17] [18] [19] . The prevalence of NESp and previously uncommon serotypes will likely continue to escalate as select serotypes are exclusively targeted by vaccines. One consequence of increased prevalence is increased cocolonization of encapsulated strains and NESp within the nasopharynx, which in turn heightens the opportunity for genetic exchange of virulence factors. Because NESp harbor unique virulence factors not identified in encapsulated strains, exchange of such genes could generate novel, hypervirulent strains [5, 6] . Additionally, selective pressure from vaccine usage forces vaccine serotypes to mutate in order to persist as pathogens. Acquisition and expression of NESp virulence genes in the place of capsule synthesis could provide vaccine-targeted pneumococci an easily attainable alternative strategy for pathogenesis. A subset of group II NESp designated null capsule clade 1 (NCC1) encode the gene for pneumococcal surface protein K (pspK) in their cps locus [5, 6] . It has been demonstrated that PspK aids in NCC1 nasopharyngeal colonization, which is a prerequisite to pneumococcal disease [20] . PspK also increases adherence to lung epithelia and persistence within the middle ear [20, 21] . Because of the natural competence of pneumococci, we predict encapsulated strains could obtain NESp virulence genes, such as pspK, as the occurrence of cocolonization rises. It is known that encapsulated strains switch capsular serotypes, which is made possible by homologous recombination at highly conserved flanking regions [18, 19, 22] . In fact, this region is considered a recombination hotspot due to abnormally high horizontal transfer of these genes [15] . Because pspK lies between the same 2 flanking regions as the cps genes, recombination to incorporate pspK into the genome could easily occur as well. Almost 90 years ago, Frederick Griffith demonstrated nonencapsulated pneumococcal isolates became encapsulated after coinfections with heatkilled encapsulated pneumococci, proving encapsulated and nonencapsulated pneumococci can exchange genes within the cps locus while in a host [23] . In Griffith's experiment, it was beneficial for the rough strains to express capsule in order to persist in the host. Now, because the capsule is under selective pressure elicited by vaccines, it becomes beneficial for vaccine serotypes to undergo selective mutagenesis and become NESp [24] .
Our lab previously demonstrated that ectopic pspK expression in the avirulent strain R36A increases epithelial cell adhesion and nasopharyngeal colonization [20] . Thus, expressing PspK in the place of capsule could help vaccine serotypes persist in the host when facing capsule-targeting antibodies. Moreover, incorporation of pspK somewhere other than the cps locus could increase the virulence of pathogenic encapsulated strains. Another NESp cps locus gene, aliD, has already been detected preceding the cps genes in certain encapsulated serotypes, indicating strains can simultaneously possess capsule synthesis genes and NESp virulence genes [25] . Because licensed pneumococcal vaccines only cover a limited number of isolates, generation of novel, hypervirulent strains could greatly exacerbate pneumococcal disease incidence.
The aim of this study was to investigate the impact PspK expression has on virulence of an encapsulated pneumococcal isolate in the context of both capsule expression and loss of capsule. This research demonstrates the risks associated with increased NESp prevalence and emphasizes the need to re-evaluate pneumococcal preventatives.
MATERIALS AND METHODS

Bacterial Strains and Growth Conditions
Strains used in these studies are described in Table 1 . Detailed descriptions of strain origin and mutant construction have been previously described [26, 27] . In brief, EF3030 (serotype 19F) was transformed with pABG5::pspK to generate the isogenic pspK + strain LEK14. An EF3030 capsule deletion mutant (LEK12) was created by allelic replacement of cps with a spectinomycin resistance cassette. LEK12 was subsequently transformed with pABG5::pspK to generate LEK15. Pneumococcal strains were grown at 37°C in 5% carbon dioxide (CO 2 ) in Todd-Hewitt broth supplemented with 0.5% yeast extract (THY) or on blood agar (BA) containing 5% sheep's blood. Strains containing selective resistance cassettes were cultured in the presence of the appropriate antibiotic (listed in Table 1 ).
Epithelial Cell Adhesion and Invasion
A549 pulmonary cells (ATCC CCL-18) and Detroit 562 pharyngeal cells (ATCC CCL-138) were used for these studies. Epithelial cells were cultured to 95% confluency in 24-well plates in 1 mL of Eagle's minimal essential medium (EMEM) containing 10% fetal calf serum, 100 µg/mL of penicillin, 100 µg/mL of amphotericin B, and 50 µg/mL of streptomycin. Plates were incubated at 37°C in 5% CO 2 . Confluent epithelial cells were rinsed in sterile phosphate-buffered saline (PBS) 3 times, and 10 7 pneumococci suspended in 1 mL of EMEM (without antibiotics) was added to each well. For adhesion assays, plates were incubated at 37°C in 5% CO 2 for 30 minutes, and each well was washed 3 times with 1 mL of PBS. Epithelial cells were trypsinized with 100 µL of 0.25% trypsin-ethylenediaminetetraacetic acid (EDTA), and 900 µL of PBS was added to bring the final volume to 1 mL. For invasion assays, plates were incubated at 37°C in 5% CO 2 for 2 hours, wells were washed with PBS 3 times, and 1 mL of EMEM containing 100 µg/mL of penicillin, 100 µg/mL of amphotericin B, and 50 µg/mL of streptomycin were added to each well for 1 hour. Each well was washed 3 times in 1 mL of PBS, trypsinized in 100 µL of 0.25% trypsin-EDTA, and lysed in 100 µL of ice cold 0.0125% Triton X-100. Adhered or invasive pneumococci were enumerated by plating on BA.
Murine Nasopharyngeal Colonization and Pneumonia
For colonization studies, adult C57BL/6 mice were anesthetized by inhalation of isoflurane and intranasally challenged with 10 µL of PBS containing 10 7 colony-forming units (CFUs) of pneumococci. Mice were killed after 5 days, nasal passages were washed with 200 µL of PBS, and nasopharyngeal tissues were collected and homogenized in 200 µL of PBS. Pneumococci were enumerated by plating samples on BA, and counts from the 2 samples were combined to determine total recovered CFUs. For lung infections, adult C57BL/6 mice were anesthetized by intraperitoneal injections of 500 µL of Avertin (2.5% amylene hydrate solution containing 6.25 mg of tribromoethanol) and intratracheally inoculated with 50 µL of PBS containing 10 7 CFUs of pneumococci. Two days after infection, lungs were collected and homogenized in 2 mL of PBS. Samples were plated on BA to enumerate CFUs. For coinfections in the nasopharynx and lungs, the methods described above were followed, except mice were inoculated with PBS containing a mixture of 5 × 10 6 CFUs of EF3030 and 5 × 10 6 CFUs of LEK14. Coinfection samples were plated on BA and BA containing 500 µg/mL of kanamycin. Counts from the 2 plates were compared to determine EF3030 CFUs and LEK14 CFUs. Competitive indices were calculated by dividing recovered EF3030 CFUs by recovered LEK14 CFUs, and statistical significance was determined by comparing these values to 1. 
Chinchilla Otitis Media
Adult chinchillas (Chinchilla lanigera) were inoculated in each bullae via transbullar injection of 100 µL of PBS containing pneumococci and 0.04% gelatin. Chinchillas infected with EF3030 or LEK14 received 10 3 CFUs in each bulla, and chinchillas infected with LEK12 or LEK15 received 10 6 CFUs in each bulla. The tympanic membranes were examined via otoscope after the chinchillas were killed 4 days after infection, and tympanic pathology was scored as follows: 0 = no visible pathology, 1 = inflammation, 2 = effusion, and 3 = tympanic membrane rupture. Biofilm formation was visually assessed by removing the top of each bulla, and biofilm levels were scored as follows: 0 = no biofilm, 1 = surface formation, 2 = traverses bulla, and 3 = traverses bulla with thickening. Any exudate present in the bulla was collected, and the bulla was washed with 1 mL of PBS. Whole bullae were then removed and homogenized in 10 mL of PBS. All samples were plated on BA, and the counts were combined to determine total recovered CFUs per bulla.
Ethics Statement
All animal studies performed were in accordance with protocols approved by the Institutional Animal Care and Use Committee of the University of Mississippi Medical Center.
Statistical Analysis
Data were compared using an unpaired Student's t test with Prism 5 software (GraphPad Software, Inc, San Diego, CA). Competitive indices were compared using a paired t test. P values < .05 indicate significance. Error bars denote standard error of the mean.
RESULTS
Epithelial Cell Adhesion and Invasion
We generated PspK + transformants in the encapsulated pneumococcal isolate EF3030. To determine effects of PspK expression in encapsulated pneumococci, we first examined epithelial cell adhesion and invasion. Expression of PspK did not affect EF3030 adherence or invasion of Detroit 562 pharyngeal cells ( Figure 1A and B) . In contrast, EF3030 had significantly greater adherence (P < .0001) and invasion (P < .0001) of A549 lung epithelial cells when PspK was expressed ( Figure 1C and D) .
Murine Nasopharyngeal Colonization and Pneumonia
Using a mouse model of infection, we examined how PspK expression affected EF3030 nasopharyngeal colonization and persistence in the lungs. To determine whether PspK expression would compensate for reduced virulence in the absence of capsule, LEK12 (EF3030Δcps) and LEK15 (LEK12::pspK) were also used. Similar to in vitro adhesion experiments using Detroit 562 pharyngeal cells ( Figure 1A ), expression of PspK in EF3030 did not alter the ability to colonize the murine nasopharynx ( Figure 2A ). However, PspK expression partially restored the loss of colonization in the capsule deletion mutant LEK12 (Figure 2A ). Our lung infection results also correlated with our in vitro studies using A549 lung epithelia ( Figure 1C ). Significantly higher CFUs (P < .001) were recovered from the lungs of mice infected with LEK14 compared with those infected with EF3030 ( Figure 2B ). Coinciding with colonization studies, PspK expression significantly increased persistence of the capsule deletion mutant in the lungs as well (P < .01) ( Figure 2B ). 
Murine Coinfections
We next determined whether PspK expression would afford encapsulated strains a selective advantage when competing with the parental strain in the host. To produce a competitive environment, mice were simultaneously inoculated with EF3030 and LEK14 at a 1:1 ratio in either the lungs or nasopharynx. Five days after infection, significantly more LEK14 was recovered from the nasopharynx in comparison with EF3030 (P < .01) ( Figure 3A) . Additionally, significantly more LEK14 was recovered from the lungs 2 days after infection (P < .0001) ( Figure 3B) . A competitive index of 1 signifies an equal ratio of recovered CFUs and therefore no advantage in a competitive environment. All competitive indices were significantly <1 (P < .0001), indicating a competitive advantage for LEK14 when grown in competition with EF3030 ( Figure 3C ).
Chinchilla Otitis Media
Because PspK is known to aid in persistence of NCC1 NESp in the middle ear, a chinchilla model was used to determine effects of PspK expression on EF3030 during OM. EF3030 CFUs increased dramatically within the middle ear during the infection period, but there was no mortality in EF3030-infected chinchillas during the 4-day infection period. However, the PspK + strain LEK14 increased to levels significantly higher than parental strain EF3030 (P < .0001) ( Figure 4A ), and 1 of the chinchillas succumbed to the infection at day 3. Moreover, recovered LEK15 CFUs were significantly higher than LEK12 CFUs (P < .0001) ( Figure 4B ). Pathology and biofilm formation within the middle ear did not differ between EF3030 and LEK14, but LEK15 had significantly higher (P < .05) pathology and biofilm scores than LEK12 ( Table 2) . CFUs. Nasopharyngeal samples were collected 5 days after infection, and lung samples were collected 2 days after infection. In both the nasopharynx (A) (P < .01) and lungs (B) (P < .0001), significantly more LEK14 was recovered in comparison with EF3030. Competitive indices were calculated by dividing recovered EF3030 CFUs by recovered LEK14 CFUs and comparing those values to 1. All values were significantly <1, (P < .0001) indicating LEK14 significantly outcompeted EF3030 (C). Abbreviations: CFUs, colony-forming units; WT, wild-type.
DISCUSSION
It was previously thought capsule production was a requirement for pneumococcal infection to occur [1, 28] . However, it has become evident that not only are NESp capable of causing serious infections, but they are also becoming increasingly more common sources of infection [6, 29, 30] . Regardless of the changes in prevalence, NESp-inclusive vaccines have yet to be developed. With horizontal gene transfer being greatly increased during dual-strain nasopharyngeal carriage [31] , encapsulated pneumococci are provided the opportunity to acquire new genetic traits as they cocolonize the nasopharynx with NESp. The aim of our studies was to assess the outcome of the virulent encapsulated pneumococcal isolate EF3030 acquiring the NESp virulence gene pspK. We hypothesized PspK would increase encapsulated virulence and allow capsule deletion mutants to persist in a host without capsule. Due to the adhesive nature of PspK, we first examined effects on adhesion and invasion of immortalized human epithelial cells. Interestingly, the presence of PspK enhanced EF3030 adhesion and invasion of human lung epithelia but did not alter interactions with pharyngeal epithelial cells (Figure 1) . These results correlate with our previous work in which we showed increased PspK expression in the NCC1 NESp MNZ67 increased adhesion to lung cells exclusively [32] . We predict this pulmonary-specific effect is due to the presence of a PspK ligand on the surface of lung epithelia that is not present on pharyngeal cells. Although A549 invasion was also increased, it has been determined PspK does not alter epithelial cell invasion when expressed in NESp [20, 32] . Therefore, we do not attribute the increased A549 invasion to PspK expression directly. Rather, the increased interaction with pulmonary cells afforded by PspKassociated adhesion likely allows the already invasive EF3030 isolate greater opportunity to invade the cells.
To support our in vitro observations, a mouse model was used to determine whether PspK impacted nasopharyngeal colonization and persistence in the lungs. Based on in vitro adhesion and invasion results, we predicted PspK would exclusively alter persistence in the lungs. As shown in Figure 2 , higher LEK14 CFUs were recovered from the murine lungs, whereas no difference in recovered CFUs was observed in mice who were intranasally infected. These results further support the idea that unique PspK ligands are located on lung epithelia.
Although the presence of PspK did not affect colonization when mice were challenged with a single strain, LEK14 significantly outcompeted EF3030 during dual-strain infections in both the nasopharynx and lungs (P < .0001) (Figure 3) . Therefore, it appears PspK provides a selective advantage in a competitive environment regardless of the location within a host. This is important because the nasopharynx is a nutritionally restricted area, and bacterial strains often must compete to survive. Although a competitive advantage c Significantly higher than LEK12 (P < .05).
was observed in both environments, it should be noted there was a greater difference between recovered EF3030 and LEK14 CFUs in the lungs than there was in the nasopharynx ( Figure 3C ). These results indicate a greater selective advantage in the lungs and further support our hypothesis of pulmonary-specific PspK interactions. PspK expression also significantly increased both colonization (P < .0001) and persistence in the lungs (P < .01) in the EF3030 capsule deletion mutant (Figure 2) . Although levels were not restored to those of wild-type EF3030, the addition of the adhesive protein PspK does partially compensate for the loss of virulence due to capsule deletion. This means acquisition of pspK could provide vaccine-targeted serotypes with an alternative route of infection when facing capsule-specific antibodies. Pneumococcal pneumonia is a major cause of morbidity and mortality in patients aged >65 years, and S. pneumoniae is the most frequently isolated pathogen in patients with community acquired pneumonia [33] [34] [35] . Based on our results, expression of PspK could increase the occurrence and severity of these pulmonary infections.
Our last in vivo model was a chinchilla model of OM. Otitis media is the most frequent cause for pediatric visits and antibiotic prescriptions to children aged <5 years in the United States, and even with vaccination implementation, pneumococcal OM rates remain high [12] [13] [14] . Therefore, acquisition of PspK by a virulent encapsulated strain such as EF3030 could exacerbate this already high disease burden. It should be noted EF3030 is highly virulent in a chinchilla, so the chinchillas were infected with a relatively low inoculum of 10 3 CFUs. During the 4-day infection period, both EF3030 and LEK14 produced high levels of middle ear effusion, which led to rupture of the tympanic membrane in some animals. Because both strains scored at the top of our pathology scoring scale, there was not a difference in visible pathology. We recovered >10 8 CFUs/mL from the EF3030-infected chinchillas, which is a considerable increase. However, LEK14 was even more successful at persisting in the host, with over 10 9 CFUs/mL recovered ( Figure 4A ). Additionally, all EF3030-infected chinchillas survived the full 4 days, but one of the LEK14-infected chinchillas died 3 days after infection. Based on these results, the outcome of a child developing OM from a PspK + encapsulated strain could have critical consequences. Furthermore, the presence of PspK again partially compensated for the loss of virulence after capsule deletion ( Figure 4B ). LEK12 had very little CFUs recovered and little to no visible pathology. In contrast, LEK15 had higher recovered CFUs, as well as high levels of inflammation and effusion. Thus, expression of PspK in the place of capsule would provide a secondary method of pathogenesis.
We conclude simultaneous expression of PspK and capsule would increase pneumococcal pneumonia and OM and could alter colonization rates by providing a selective advantage during cocolonization. Additionally, where loss of capsule reduces colonization and disease development, PspK expression would allow a capsule deletion mutant to persist in the host. A major issue that should be of concern is that we do not know whether genetic exchange of NESp virulence genes into encapsulated pneumococci is already occurring naturally. Pneumococcal isolates are typically only screened for NESp virulence genes if they lack the capsule synthesis gene cpsA and are labeled nontypeable. To determine the occurrence of intraspecies genetic exchange, encapsulated pneumococcal isolates need to be screened for the presence of NESp-specific genes. Altogether, our studies demonstrate the risks associated with increased NESp prevalence, validate the need to increase NESp surveillance, and reinforce the necessity to develop NESp-inclusive preventatives.
Notes
